-
The National Health and Medical Commission publicly solicits opinions on the "Working Plan for the Temporary Import of Drugs Urgently Needed in Clinical Practice"
Time of Update: 2022-04-20
On March 29, the National Health and Medical Commission and the State Food and Drug Administration publicly solicited opinions on the "Working Plan for Temporary Import of Drugs Urgently Needed in Cl
-
Sprinting into the 1.9 billion injection market, Sinopharm Group's application for doxofylline injection was accepted
Time of Update: 2022-04-20
Sales of terminal doxofylline injection in Chinese public medical institutions (unit: ten thousand yuan)Source: Minet.
com China's public medical institutions terminal competition patternUp to now, doxofylline injection has been reviewed by 14 companies, including Fuhe Pharmaceutical, Fuan Pharmaceutical, Yangzijiang, Shijiazhuang No.
-
Personnel changes in a number of pharmaceutical companies involve Pfizer, Simcere...
Time of Update: 2022-04-20
It is understood that Zhao Ping also announced the news to CStone employees in the company's WeChat group on March 28 and said goodbye to everyone .
-
The State Food and Drug Administration has approved 20 new coronavirus antigen detection reagents
Time of Update: 2022-04-20
(Finish) On March 29, after review by the State Food and Drug Administration, a new coronavirus antigen detection reagent product was approved .
(Finish) On March 29, after review by the State Food and Drug Administration, a new coronavirus antigen detection reagent product was approved .
-
The Shanghai Municipal People's Government issued policies and measures to fight the epidemic to help enterprises promote development
Time of Update: 2022-04-20
Promote government financing guarantee institutions to provide financing and credit enhancement support for eligible micro, small and medium-sized enterprises and individual industrial and commercial households, perform compensatory responsibilities in a timely manner in accordance with the law, help enterprises that have been greatly affected by the epidemic to renew their insurance and renew loans, and increase support for those affected by the epidemic.
-
FDA approves GSK's long-acting HIV drug Cabenuva for teens
Time of Update: 2022-04-19
Reference source: ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
-
Recently, a number of domestic new drugs have been approved for marketing at home and abroad
Time of Update: 2022-04-19
According to the recent announcements of major pharmaceutical companies, NMPA and other information, a large number of domestic new drugs have been approved for marketing since March, and more than ten drugs have been approved for marketing at home and abroad since March, involving Hansoh Pharmaceutical and Junshi Biotechnology.
-
Strengthen the needle and then strengthen it!
Time of Update: 2022-04-19
In addition, the FDA has authorized the vaccine for a second booster dose for individuals 12 years of age and older, identified as having certain immunocompromised conditions, who have received any of the approved COVID-19 boosters .
-
Yichang Renfu submitted a marketing application for Azithromycin Dry Suspension to impact the first review
Time of Update: 2022-04-19
Figure 2: 2021E Share of Azithromycin Dry Suspension Top 5 Enterprises in China's Urban Physical Pharmacy Terminals Source: Minenet country city physical pharmacy terminal At present, the azithromycin dry suspension in the retail market is mainly led by Pfizer, with a market share as high as 80%, and more than 20 domestic enterprises have obtained production approvals .
-
100 million US dollars to help develop precision Parkinson's disease treatment The main drug enters clinical development this year
Time of Update: 2022-04-19
The company said it has identified a potential "best-in-class" blood-brain barrier-crossing LRRK2 inhibitor called NEU-723 as a clinical candidate for Parkinson's disease .
References:[1] Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease.
Retrieved March 30, 2022, from https:// c-financing-round-nominates-clinical-candidate-for-parkinsons-disease-301513270.
-
The domestic pharmaceutical industry has entered a new round of transformation and pain, and the adjustment of executives of multinational pharmaceutical companies has accelerated
Time of Update: 2022-04-19
It is worth noting that some of these companies have frequent personnel changes and have successively announced the appointment of a number of executives .
-
Yifan Pharmaceutical: FDA will delay approval of F-627 marketing application
Time of Update: 2022-04-19
This time, the controlled subsidiary received a notification from the FDA that the FDA was unable to conduct on-site inspections of the subsidiary's production due to travel restrictions and delayed the approval of the F-627 listing application.
-
Sprinting for the second domestic Hansoh Pharmaceutical Co., Ltd. accepted the application for production of Vinorelbine tartrate soft capsules
Time of Update: 2022-04-19
A few days ago, CDE's official website showed that Jiangsu Hansoh Pharmaceutical's Vinorelbine tartrate soft capsules were accepted for production as a 4-type imitation, and it will be regarded as over-evaluation after approval .
-
Breast cancer drug price war has started!
Time of Update: 2022-04-19
As the first antibody-conjugated drug (ADC) marketed in the field of breast cancer in China, this product has brought good news to the majority of patients .
-
Adagio's new crown antibody phase II/III study was successful!
Time of Update: 2022-04-19
In the primary efficacy analysis of the pre-exposure prophylaxis (PrEP) cohort in the EVADE study, adintrevima reduced the relative risk by 71% over the 3-month period compared to the placebo group by month 3 or at the onset of Omicron .
-
Hengrui Medicine's research results of camrelizumab appeared again at the European Lung Cancer Congress and made a new breakthrough in the treatment of squamous NSCLC!
Time of Update: 2022-04-19
As a result, the CameL-sq study has refreshed the current median overall survival record of the phase III randomized controlled trial (RCT) of immunotherapy combined with chemotherapy in the first-line treatment of advanced lung squamous cell carcinoma, and camrelizumab combined with chemotherapy has created a new survival data height (including median OS and 3-year OS rate) [3], bringing a new breakthrough in the field .
-
Luye Pharma Grants Exeltis Exclusive Commercialization Rights for New Drugs in Mexico, Poland
Time of Update: 2022-04-19
It is reported that the sales of Ristigmine multiday transdermal patch in the European market is the responsibility of the company's local branches and partners; the company also has the exclusive rights to develop and commercialize the product in Japan, as well as the exclusive rights in mainland China.
-
Corning Jereh's first phase III study of PD-L1/CTLA-4 double antibody successfully submitted a marketing application
Time of Update: 2022-04-19
First interim analysis by the Independent Data Monitoring Committee (iDMC), KN046 plus platinum-based chemotherapy versus placebo plus Platinum chemotherapy resulted in a significant and clinically meaningful prolongation of progression-free survival (PFS) in patients with advanced squamous non-small cell lung cancer, meeting pre-specified superiority criteria .
-
What are the new trends in the clinical research of innovative drugs to overcome ankylosing spondylitis?
Time of Update: 2022-04-19
Transfer from | Medicine GuanlanWith the breakthroughs in the treatment of ankylosing spondylitis (AS) with two novel drugs, interleukin-17 (IL-17) inhibitors and JAK inhibitors, the development of new drugs in this disease field has become more active, and clinical research has also been reported frequently Good news .
-
All localities are vigorously carrying out special rectification actions for drug safety, and the pharmaceutical industry will face stricter supervision
Time of Update: 2022-04-19
. Since the beginning of this year, drug supervision departments at all levels in Jiangsu Province have intensified drug inspection and law enforcement when carrying out special drug safety rectification actions .
